Conditions: Vitreomacular Traction Vitreomacular Adhesion
Keywords: VMT sVMA vitrectomy ocriplasmin
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 62
Healthy volunteers: no

Brief summary:
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.

Detailed description:

Arms:
arm 1: Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal (IVT) injection

Interventions: intervention 1: Ocriplasmin 0.125 mg in a 0.1 mL volume
Intervention descriptions: intervention 1: None

Protocol document: